XML 196 R3.htm IDEA: XBRL DOCUMENT
v3.25.1

Award Timing Disclosure | 12 Months Ended |
--- | --- | ---
Dec. 31, 2024 | Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | Mar. 10, 2024 USD ($) shares $ / shares
Awards Close in Time to MNPI Disclosures [Table] |  |  |  |  |  |
Award Timing MNPI Disclosure | The Compensation and Talent Committee generally approves the target value of annual equity awards for the Company’s executive officers, including each of the Named Executive Officers, at its regularly scheduled meeting in late January or early February of each year, with a grant date to be effective on March 10th, which is generally following the filing of our Annual Report on Form 10-K for the prior year. Annual equity awards to other company employees are typically approved by our CEO with a grant date of March 10th as well. Additionally, employees may enroll to purchase shares of the Company’s common stock under the terms of the Gilead Sciences, Inc. Employee Stock Purchase Plan, with purchase dates generally in February and August of each year. In special circumstances, including the hiring or promotion of an individual or where the Committee or its authorized delegate determines it is in the best interest of the Company, the Committee or its delegate may approve grants throughout the year, with such grants effective on the 10th day of each calendar month or at other times determined to be appropriate. The Company may change these practices in the future. The Company does not time the disclosure of material nonpublic information for the purpose of affecting the value of executive compensation. Consistent with the above-described practice, on March 10, 2024, the Committee granted our Named Executive Officers annual equity awards including stock options, restricted stock units and performance shares. This pre-approved grant was made four days before the Company filed a Form 8-K disclosing that Kevin E. Lofton had notified the Board of his decision to retire from the Board, effective as of the conclusion of his term at Gilead’s next annual meeting of stockholders held on May 8, 2024. Due to this Form 8-K event, as required by SEC rules, the table below sets forth certain information about the annual stock option grants made to our Named Executive Officers.
Name |  | Grant Date |  | Number of Securities Underlying the Award |  | Exercise Price of the Award ($/Sh) |  | Grant Date Fair Value of the Award |  | Percentage Change in the Closing Market Price of the Securities Underlying the Award Between the Trading Day Ending Immediately Prior to the Disclosure of Material Nonpublic Information and the Trading Day Beginning Immediately Following the Disclosure of Material Nonpublic Information(1) |
Daniel P. O’Day |  | March 10, 2024 |  |  | 279,130 |  |  | $ | 75.12 |  |  | $ | 4,125,011 |  |  |  | (2.96) | %
Andrew D. Dickinson |  | March 10, 2024 |  |  | 87,970 |  |  | $ | 75.12 |  |  | $ | 1,300,029 |  |  |  | (2.96) | %
Johanna Mercier |  | March 10, 2024 |  |  | 87,970 |  |  | $ | 75.12 |  |  | $ | 1,300,029 |  |  |  | (2.96) | %
Merdad V. Parsey, M.D., Ph.D. |  | March 10, 2024 |  |  | 89,660 |  |  | $ | 75.12 |  |  | $ | 1,325,004 |  |  |  | (2.96) | %
Deborah H. Telman |  | March 10, 2024 |  |  | 54,980 |  |  | $ | 75.12 |  |  | $ | 812,500 |  |  |  | (2.96) | %
(1) | Reflects the percentage change in the closing market price of our common stock between the trading day ending immediately prior to the Form 8-K filing ($75.94 on March 13, 2024) and the trading day beginning immediately following the disclosure of material nonpublic information ($73.69 on March 15, 2024).
Award Timing Method | The Compensation and Talent Committee generally approves the target value of annual equity awards for the Company’s executive officers, including each of the Named Executive Officers, at its regularly scheduled meeting in late January or early February of each year, with a grant date to be effective on March 10th, which is generally following the filing of our Annual Report on Form 10-K for the prior year. Annual equity awards to other company employees are typically approved by our CEO with a grant date of March 10th as well. Additionally, employees may enroll to purchase shares of the Company’s common stock under the terms of the Gilead Sciences, Inc. Employee Stock Purchase Plan, with purchase dates generally in February and August of each year. In special circumstances, including the hiring or promotion of an individual or where the Committee or its authorized delegate determines it is in the best interest of the Company, the Committee or its delegate may approve grants throughout the year, with such grants effective on the 10th day of each calendar month or at other times determined to be appropriate. The Company may change these practices in the future. The Company does not time the disclosure of material nonpublic information for the purpose of affecting the value of executive compensation. |  |  |  |  |
Award Timing Predetermined | true |  |  |  |  |
Award Timing, How MNPI Considered | The Company does not time the disclosure of material nonpublic information for the purpose of affecting the value of executive compensation. |  |  |  |  |
MNPI Disclosure Timed for Compensation Value | false |  |  |  |  |
Disclosure - Award Timing Disclosure |
Name |  | Grant Date |  | Number of Securities Underlying the Award |  | Exercise Price of the Award ($/Sh) |  | Grant Date Fair Value of the Award |  | Percentage Change in the Closing Market Price of the Securities Underlying the Award Between the Trading Day Ending Immediately Prior to the Disclosure of Material Nonpublic Information and the Trading Day Beginning Immediately Following the Disclosure of Material Nonpublic Information(1) |
Daniel P. O’Day |  | March 10, 2024 |  |  | 279,130 |  |  | $ | 75.12 |  |  | $ | 4,125,011 |  |  |  | (2.96) | %
Andrew D. Dickinson |  | March 10, 2024 |  |  | 87,970 |  |  | $ | 75.12 |  |  | $ | 1,300,029 |  |  |  | (2.96) | %
Johanna Mercier |  | March 10, 2024 |  |  | 87,970 |  |  | $ | 75.12 |  |  | $ | 1,300,029 |  |  |  | (2.96) | %
Merdad V. Parsey, M.D., Ph.D. |  | March 10, 2024 |  |  | 89,660 |  |  | $ | 75.12 |  |  | $ | 1,325,004 |  |  |  | (2.96) | %
Deborah H. Telman |  | March 10, 2024 |  |  | 54,980 |  |  | $ | 75.12 |  |  | $ | 812,500 |  |  |  | (2.96) | %
Adjustment To PEO Compensation, Footnote [Text Block] |
(2) | The dollar amounts reported represent the amount of “compensation actually paid”, as computed in accordance with SEC rules, for Mr. O’Day. The dollar amounts do not reflect the actual amount of compensation earned by or paid during the applicable year. In accordance with SEC rules, the following adjustments were made to total compensation to determine the compensation actually paid:
| Year |  | Summary Compensation Table Total for Mr. O’Day |  |  | Less: Summary Compensation Table Reported Value of Equity Awards(a) |  |  | Plus: Equity Award Adjustments(b) |  |  | Equals: Compensation Actually Paid to Mr. O’Day |
| 2024 |  | $ | 23,689,392 |  |  | $ | 16,551,827 |  |  | $ | 37,647,814 |  |  | $ | 44,785,379 |
| 2023 |  | $ | 22,607,690 |  |  | $ | 15,615,056 |  |  | $ | 8,491,149 |  |  | $ | 15,483,783 |
| 2022 |  | $ | 21,621,253 |  |  | $ | 14,353,915 |  |  | $ | 47,697,917 |  |  | $ | 54,965,255 |
| 2021 |  | $ | 19,229,466 |  |  | $ | 13,139,064 |  |  | $ | 25,394,946 |  |  | $ | 31,485,348 |
| 2020 |  | $ | 18,998,095 |  |  | $ | 11,513,097 |  |  | $ | 8,632,324 |  |  | $ | 16,117,322 |
(a) | Represents the aggregate grant-date fair value of equity awards as reported in the “Stock Awards” and “Option Awards” columns in the Summary Compensation Table for the applicable year.
(b) | The equity award adjustments for each applicable year were as set forth in the table below. The valuation assumptions used to calculate fair values did not materially differ from those disclosed at the time of grant. The amounts deducted or added in calculating the equity award adjustments are as follows:
| Year |  | Year End Fair Value of Equity Awards Granted during the Year |  |  | Year over Year Change in Fair Value of Outstanding and Unvested Equity Awards Granted in Prior Years |  |  | Year over Year Change in Fair Value of Equity Awards Granted in Prior Years that Vested during the Year |  |  | Value of Dividend Equivalents Accrued or Other Earnings Paid on Stock Awards Not Otherwise Reflected in Fair Value |  |  | Total Equity Award Adjustments |
| 2024 |  | $ | 23,956,270 |  |  | $ | 13,333,936 |  |  | $ | (1,033,888 | ) |  | $ | 1,391,496 |  |  | $ | 37,647,814 |
| 2023 |  | $ | 12,525,814 |  |  | $ | (2,481,113 | ) |  | $ | (2,859,625 | ) |  | $ | 1,306,073 |  |  | $ | 8,491,149 |
| 2022 |  | $ | 34,153,918 |  |  | $ | 14,183,571 |  |  | $ | (1,966,582 | ) |  | $ | 1,327,010 |  |  | $ | 47,697,917 |
| 2021 |  | $ | 17,162,219 |  |  | $ | 6,011,125 |  |  | $ | 707,262 |  |  | $ | 1,514,340 |  |  | $ | 25,394,946 |
| 2020 |  | $ | 8,885,442 |  |  | $ | (1,693,496 | ) |  | $ | 409,911 |  |  | $ | 1,030,467 |  |  | $ | 8,632,324 |
PEO Name | Mr. O’Day | Mr. O’Day | Mr. O’Day | Mr. O’Day | Mr. O’Day |
Adjustment to Non-PEO NEO Compensation Footnote [Text Block] |
(4) | The dollar amounts reported represent the average amount of “compensation actually paid” to the NEOs identified in footnote 3, as computed in accordance with SEC rules. The dollar amounts do not reflect the actual amount of compensation earned by or paid to any NEO during the applicable year. In accordance with SEC rules, the following adjustments were made to average total compensation for the NEOs for each year to determine the compensation actually paid:
| Year |  | Average Reported Summary Compensation Table Total for Other NEOs |  |  | Less: Summary Compensation Table Average Reported Value of Equity Awards |  |  | Plus: Average Equity Award Adjustments(a) |  |  | Equals: Average Compensation Actually Paid to Other NEOs |
| 2024 |  | $ | 7,725,458 |  |  | $ | 4,828,738 |  |  | $ | 11,290,250 |  |  | $ | 14,186,970 |
| 2023 |  | $ | 7,588,163 |  |  | $ | 4,809,225 |  |  | $ | 2,690,199 |  |  | $ | 5,469,137 |
| 2022 |  | $ | 7,874,828 |  |  | $ | 4,961,052 |  |  | $ | 15,268,810 |  |  | $ | 18,182,586 |
| 2021 |  | $ | 6,279,776 |  |  | $ | 3,625,534 |  |  | $ | 7,038,936 |  |  | $ | 9,693,178 |
| 2020 |  | $ | 6,616,768 |  |  | $ | 3,087,064 |  |  | $ | 2,596,731 |  |  | $ | 6,126,435 |
(a) | The amounts deducted or added in calculating the total average equity award adjustments are as follows:
| Year |  | Average Year End Fair Value of Equity Awards Granted During the Year |  |  | Year over Year Average Change in Fair Value of Outstanding and Unvested Equity Awards Granted in Prior Years |  |  | Year over Year Average Change in Fair Value of Equity Awards Granted in Prior Years that Vested in the Year |  |  | Average Value of Dividend Equivalents Accrued or Other Earnings Paid on Stock Awards Not Otherwise Reflected in Fair Value |  |  | Total Average Equity Award Adjustments |
| 2024 |  | $ | 6,878,321 |  |  | $ | 4,260,282 |  |  | $ | (282,467 | ) |  | $ | 434,114 |  |  | $ | 11,290,250 |
| 2023 |  | $ | 3,955,902 |  |  | $ | (789,322 | ) |  | $ | (879,498 | ) |  | $ | 403,117 |  |  | $ | 2,690,199 |
| 2022 |  | $ | 11,751,514 |  |  | $ | 3,365,229 |  |  | $ | (289,102 | ) |  | $ | 441,169 |  |  | $ | 15,268,810 |
| 2021 |  | $ | 4,989,853 |  |  | $ | 1,461,574 |  |  | $ | 271,571 |  |  | $ | 315,938 |  |  | $ | 7,038,936 |
| 2020 |  | $ | 2,488,166 |  |  | $ | (365,446 | ) |  | $ | 269,145 |  |  | $ | 204,866 |  |  | $ | 2,596,731 |
Peer Group Issuers, Footnote [Text Block] |
(6) | The peer group used for this purpose is Nasdaq Biotechnology Index.
O Day [Member] |  |  |  |  |  |
Awards Close in Time to MNPI Disclosures [Table] |  |  |  |  |  |
Awards Close in Time to MNPI Disclosures, Individual Name |  |  |  |  |  | Daniel P. O’Day
Award Underlying Securities Amount | shares |  |  |  |  |  | 279,130
Award Exercise Price | $ / shares |  |  |  |  |  | $ 75.12
Award Grant Date Fair Value | $ |  |  |  |  |  | $ 4,125,011
Underlying Security Market Price Change, Percent |  |  |  |  |  | (0.0296)
Dickinson [Member] |  |  |  |  |  |
Awards Close in Time to MNPI Disclosures [Table] |  |  |  |  |  |
Awards Close in Time to MNPI Disclosures, Individual Name |  |  |  |  |  | Andrew D. Dickinson
Award Underlying Securities Amount | shares |  |  |  |  |  | 87,970
Award Exercise Price | $ / shares |  |  |  |  |  | $ 75.12
Award Grant Date Fair Value | $ |  |  |  |  |  | $ 1,300,029
Underlying Security Market Price Change, Percent |  |  |  |  |  | (0.0296)
Mercier [Member] |  |  |  |  |  |
Awards Close in Time to MNPI Disclosures [Table] |  |  |  |  |  |
Awards Close in Time to MNPI Disclosures, Individual Name |  |  |  |  |  | Johanna Mercier
Award Underlying Securities Amount | shares |  |  |  |  |  | 87,970
Award Exercise Price | $ / shares |  |  |  |  |  | $ 75.12
Award Grant Date Fair Value | $ |  |  |  |  |  | $ 1,300,029
Underlying Security Market Price Change, Percent |  |  |  |  |  | (0.0296)
Parsey [Member] |  |  |  |  |  |
Awards Close in Time to MNPI Disclosures [Table] |  |  |  |  |  |
Awards Close in Time to MNPI Disclosures, Individual Name |  |  |  |  |  | Merdad V. Parsey, M.D., Ph.D.
Award Underlying Securities Amount | shares |  |  |  |  |  | 89,660
Award Exercise Price | $ / shares |  |  |  |  |  | $ 75.12
Award Grant Date Fair Value | $ |  |  |  |  |  | $ 1,325,004
Underlying Security Market Price Change, Percent |  |  |  |  |  | (0.0296)
Telman [Member] |  |  |  |  |  |
Awards Close in Time to MNPI Disclosures [Table] |  |  |  |  |  |
Awards Close in Time to MNPI Disclosures, Individual Name |  |  |  |  |  | Deborah H. Telman
Award Underlying Securities Amount | shares |  |  |  |  |  | 54,980
Award Exercise Price | $ / shares |  |  |  |  |  | $ 75.12
Award Grant Date Fair Value | $ |  |  |  |  |  | $ 812,500
Underlying Security Market Price Change, Percent |  |  |  |  |  | (0.0296)

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_AdjToNonPeoNeoCompFnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_AdjToPeoCompFnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection x -Paragraph 2 -Subparagraph ii -Sentence D + Details
Name: | ecd_AwardExrcPrice
Namespace Prefix: | ecd_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection x -Paragraph 2 -Subparagraph ii -Sentence E + Details
Name: | ecd_AwardGrantDateFairValue
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | instant

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection x -Paragraph 1 + Details
Name: | ecd_AwardTmgHowMnpiCnsdrdTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection x -Paragraph 1 + Details
Name: | ecd_AwardTmgMethodTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection x -Paragraph 1 + Details
Name: | ecd_AwardTmgMnpiDiscTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection x -Paragraph 1 + Details
Name: | ecd_AwardTmgPredtrmndFlag
Namespace Prefix: | ecd_
Data Type: | xbrli:booleanItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection x -Paragraph 2 -Subparagraph ii -Sentence C + Details
Name: | ecd_AwardUndrlygSecuritiesAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:decimalItemType
Balance Type: | na
Period Type: | instant

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection x -Paragraph 2 -Subparagraph ii -Sentence A + Details
Name: | ecd_AwardsCloseToMnpiDiscIndName
Namespace Prefix: | ecd_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | instant

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection x -Paragraph 2 + Details
Name: | ecd_AwardsCloseToMnpiDiscTable
Namespace Prefix: | ecd_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection x -Paragraph 2 + Details
Name: | ecd_AwardsCloseToMnpiDiscTableTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection x -Paragraph 1 + Details
Name: | ecd_MnpiDiscTimedForCompValFlag
Namespace Prefix: | ecd_
Data Type: | xbrli:booleanItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iv + Details
Name: | ecd_PeerGroupIssuersFnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_PeoName
Namespace Prefix: | ecd_
Data Type: | xbrli:normalizedStringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection x -Paragraph 2 -Subparagraph ii -Sentence F + Details
Name: | ecd_UndrlygSecurityMktPriceChngPct
Namespace Prefix: | ecd_
Data Type: | xbrli:pureItemType
Balance Type: | na
Period Type: | instant

X
- Details
Name: | ecd_IndividualAxis=gild_ODayMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_IndividualAxis=gild_DickinsonMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_IndividualAxis=gild_MercierMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_IndividualAxis=gild_ParseyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_IndividualAxis=gild_TelmanMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |